Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

GET-IN The GEne Therapy INnovation Training Network

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 September 2023 to 31 August 2027
Status
Running
EU funding
€2.6m
Total cost
—
Partners
16 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119880

What the project is doing

In the project's own words, from its summary on CORDIS.

Gene therapy has transitioned from a distant hope to reality. To date 3 rAAV gene therapies are approved in the EU, >30 phase III clinical trials ongoing, and exciting developments in therapeutic gene editing in the pipeline. However, fundamental limitations in the bioprocessing of gene therapy vectors limit broader application. Manufacturing is not automated, with an open process environment, limited scalability and robustness, and inefficient downstream processing, resulting in huge footprint and exceedingly high cost of goods.

The field requires scalable manufacturing technology with modular design to produce high doses for large patient groups at a fraction of cost. Improved delivery approaches with increased specificity and efficacy at lower doses are needed to overcome emerging safety concerns observed in clinical trials. Prediction of therapeutic efficacy in man is challenging due to a species barrier, underlining the need for humanized models to reduce attrition rates in the development pipeline.

To overcome these challenges, innovation driven by multidisciplinary approaches is direly needed. GET-IN is a doctoral network of 7 academic and 8 non-academic partners, with expertise in vectorology, genome editing, process engineering, biomanufacturing and innovative humanized models. Together, they provide an excellent training framework for 10 Doctoral Candidates (DCs) who will be the future innovators in the gene therapy field.

Research in GET-IN will investigate disruptive innovations including optimised bioprocessing, digital simulation, novel and improved vectors and genome editors, targeted delivery systems, and human organ-on-chip models for more relevant safety and efficacy evaluation. The joint training programme will emphasise responsible, cooperative research and innovation, creativity, and entrepreneurship to maximize the career potential of the DCs.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
AntleronLouvainBelgiumParticipant
Ucb Pharma SABruxelles / BrusselBelgiumAssociatedpartner
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Miltenyi Biotec GmbHBergish GladbachGermanyAssociatedpartner
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite Cote D'azurNiceFranceAssociatedpartner
Alia TherapeuticsMilanoItalyAssociatedpartner
Alia TherapeuticsMilanoItalyParticipant
Universita Degli Studi Di TrentoTrentoItalyParticipant
Eatris EricAmsterdamNetherlandsAssociatedpartner
Mimetas BVLeidenNetherlandsParticipant
Universiteit LeidenLeidenNetherlandsAssociatedpartner
Siemens Process Systems Engineering LimitedLondonUnited KingdomAssociatedpartner
Mary Ann Liebert, Inc.New RochelleUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI